Please login to the form below

Not currently logged in
Email:
Password:

lasmiditan

This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.

Lilly set to head to regulators with CGRP migraine drug

Lilly set to head to regulators with CGRP migraine drug

Lilly recently added to its galcanezumab programme in migraine by buying CoLucid and its lead drug lasmiditan, an oral serotonin 5-HT 1F agonist that is due to be filed for

Latest news

  • Lilly to buy migraine drug developer CoLucid for $960m Lilly to buy migraine drug developer CoLucid for $960m

    Deal revolves around lasmiditan, which the firm out-licensed in 2005.  . Eli Lilly has agreed a $960m deal to buy CoLucid, claiming rights to a migraine therapy that works in a ... Lasmiditan's different mechanism means it could become the first drug

  • Migraine drugs' headache Migraine drugs' headache

    CoLucid Pharmaceuticals is developing lasmiditan, which specifically agonises the serotonin 1F receptor.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics